Orexo AB (publ) (FRA:C5G)
Germany · Delayed Price · Currency is EUR | Market Cap | 41.69M -35.3% |
| Revenue (ttm) | 1.50M -12.5% |
| Net Income | 41.60M |
| EPS | 1.20 |
| Shares Out | n/a |
| PE Ratio | 1.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.144 |
| Previous Close | 1.176 |
| Day's Range | 1.144 - 1.144 |
| 52-Week Range | 1.144 - 3.825 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powd... [Read more]
News
Orexo AB Earnings Call Transcript: Q2 2026
Transformation continued with one-time costs and staff reductions, while R&D advanced key AmorphOX-based projects. Financials showed negative cash flow and higher OpEx due to settlements and legal fees, with SEK 233 million cash remaining. DOJ settlement and partnering efforts remain key near-term priorities.
Orexo AB Quarterly report: Q2 2026
Orexo AB has published its Q2 2026 quarterly earnings report on July 16, 2026.
Orexo AB Slides: Q2 2026
Orexo AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Orexo AB Slides: ABGSC Investor Days
Orexo AB has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2026.
Orexo AB Earnings Call Transcript: Q1 2026
Divestment of Zubsolv completed, shifting focus to proprietary pipeline and technology partnerships. Net revenue was SEK 5 million, with significant transition-related payments and ongoing DOJ investigation. Key clinical milestones and partnerships are expected to drive future value.
Orexo AB Quarterly report: Q1 2026
Orexo AB has published its Q1 2026 quarterly earnings report on April 28, 2026.
Orexo AB Slides: Q1 2026
Orexo AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Orexo AB Transcript: R&D Day
AmorphOX is now the exclusive R&D focus, with late-stage projects OX640 and IZIPRY prioritized for value creation. Key milestones include FDA filings, pivotal trials, and expanding partnerships, supported by a strong financial position post-Zubsolv sale.
Orexo AB Slides: R&D Day
Orexo AB has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Orexo AB Slides: FY 2026
Orexo AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 17, 2026.
Invitation & Agenda: Orexo R&D Day on March 24
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026.
Orexo changes the organizational structure and management team to increase focus on development of new products
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team.
Orexo AB Earnings Call Transcript: Q4 2025
Divestment of Zubsolv U.S. to Dexcel Pharma brought significant cash inflow and a strategic pivot to the AmorphOX platform, with a leaner organization and focus on R&D. Continued operations saw negative EBITDA in Q4, but the company is well-capitalized for at least two years.
Orexo AB Annual report: Q4 2025
Orexo AB has published its Q4 2025 annual report on February 5, 2026.
Orexo AB Quarterly report: Q4 2025
Orexo AB has published its Q4 2025 quarterly earnings report on February 5, 2026.
Orexo AB Slides: Q4 2025
Orexo AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
Orexo AB Transcript: Investor Update
U.S. rights to Zubsolv were sold to Dexcel Pharma for $91 million plus potential earn-outs, enabling debt redemption and funding for pipeline projects. Organizational changes include U.S. staff transfer and streamlined operations, while the company focuses on advancing its development pipeline and partnering opportunities.
Orexo AB Press release: Investor Update
Orexo AB issued a press release on December 23, 2025, disclosing material business information to investors.
Orexo AB Earnings Call Transcript: Q3 2025
Q3 saw strong R&D progress, especially in GLP-1 and OX390, with BARDA funding secured for the latter. Revenue declined year-over-year due to FX and contract impacts, but gross margin improved and 2025 positive EBITDA guidance is reaffirmed.
Orexo AB Quarterly report: Q3 2025
Orexo AB has published its Q3 2025 quarterly earnings report on October 23, 2025.
Orexo AB Slides: Q3 2025
Orexo AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 23, 2025.
Orexo AB Transcript: Investing in Life Science 2025
Sales remain strong with positive EBITDA, driven by Zubsolv and a robust U.S. presence. The pipeline features innovative nasal delivery products and the AmorphOX platform, which enables stable, high-bioavailability formulations for both small and large molecules. Partnership discussions and market adaptation are ongoing.
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared wi...
Orexo AB Slides: DNB Carnegie Småbolagsdag
Orexo AB has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2025.
Orexo AB Earnings Call Transcript: Q2 2025
Q2 results were impacted by a one-time SEK 9 million rebate and negative FX, but core U.S. business remained stable with improved margins and cost control. Pipeline progress continued for OX124 (IC3) and OX640, and 2025 guidance was reaffirmed.